Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
- PMID: 8622063
- DOI: 10.1200/JCO.1996.14.5.1495
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
Abstract
Purpose: To perform a phase I clinical and pharmacologic study of ZD1694 (Tomudex, Alderley Park, United Kingdom), a new folate-based thymidylate synthase (TS) inhibitor, in patients with advanced malignancy.
Patients and methods: From February 1991 to January 1993, 61 patients with a range of solid tumor received 161 courses of ZD1694 given as a single 15-minute intravenous infusion every 3 weeks, at escalating doses from 0.1 to 3.5 mg/m2. Pharmacokinetic (PK) analysis was performed with the first two courses of treatment. There were 33 men and 28 women with a median age of 53 years (range, 21 to 73). Fifty-five patients (90%) had previously received chemotherapy.
Results: Reversible liver toxicity and dose-related gastrointestinal (GI) and bone marrow toxicity occurred at > or = 1.6 mg/m2. Liver function usually returned to normal with repeated treatment, but GI and bone marrow toxicities generally became more severe. No renal toxicity was observed. The maximum-tolerated dose (MTD) was 3.5 mg/m2, at which, in addition to antiproliferative toxicities, four of six patients (67%) developed severe malaise that consisted of anorexia, nausea, and asthenia, with rapidly decreasing performance status that limited re-treatment. Abnormal liver function was also seen in four patients (67%). At 3.0 mg/m2, grades III and IV diarrhea were seen in six of 23 patients (26%) and grade IV myelosuppression in two others. Liver toxicity was self-limiting and not associated with severe malaise. Two patients had a partial response to treatment. PK analysis showed that plasma elimination was triexponential, with pronounced variability in the mean terminal half-life (t1/2gamma) for a given dose ranging from 8.2 to 105 hours. There was a linear relationship between dose and both the area under the concentration-time curve (AUC) and maximum concentration (Cmax), but no clear association between these parameters and response or toxicity.
Conclusion: The dose of ZD1694 recommended for phase II trials is 3.0 mg/m2.
Similar articles
-
Clinical and preclinical pharmacokinetics of raltitrexed.Clin Pharmacokinet. 2000 Dec;39(6):429-43. doi: 10.2165/00003088-200039060-00004. Clin Pharmacokinet. 2000. PMID: 11192475 Review.
-
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.Clin Cancer Res. 1999 Sep;5(9):2381-91. Clin Cancer Res. 1999. PMID: 10499608 Clinical Trial.
-
[Phase I study of raltitrexed (ZD-1694)].Gan To Kagaku Ryoho. 1998 Nov;25(13):2075-84. Gan To Kagaku Ryoho. 1998. PMID: 9838910 Clinical Trial. Japanese.
-
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.J Clin Oncol. 1996 Mar;14(3):716-21. doi: 10.1200/JCO.1996.14.3.716. J Clin Oncol. 1996. PMID: 8622016 Clinical Trial.
-
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82. doi: 10.1016/0959-8049(95)00166-g. Eur J Cancer. 1995. PMID: 7577036 Review.
Cited by
-
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.Br J Cancer. 2007 May 7;96(9):1358-67. doi: 10.1038/sj.bjc.6603726. Epub 2007 Apr 10. Br J Cancer. 2007. PMID: 17426706 Free PMC article.
-
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1. Invest New Drugs. 2006. PMID: 16380836 Review. No abstract available.
-
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.Br J Clin Pharmacol. 2004 Apr;57(4):416-26. doi: 10.1111/j.1365-2125.2003.02050.x. Br J Clin Pharmacol. 2004. PMID: 15025739 Free PMC article. Clinical Trial.
-
Clinical and preclinical pharmacokinetics of raltitrexed.Clin Pharmacokinet. 2000 Dec;39(6):429-43. doi: 10.2165/00003088-200039060-00004. Clin Pharmacokinet. 2000. PMID: 11192475 Review.
-
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.Jpn J Cancer Res. 2001 Jan;92(1):74-82. doi: 10.1111/j.1349-7006.2001.tb01050.x. Jpn J Cancer Res. 2001. PMID: 11173547 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources